450 related articles for article (PubMed ID: 31156623)
1. Exploring the Immunological Mechanisms Underlying the Anti-vascular Endothelial Growth Factor Activity in Tumors.
de Aguiar RB; de Moraes JZ
Front Immunol; 2019; 10():1023. PubMed ID: 31156623
[TBL] [Abstract][Full Text] [Related]
2. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
3. Combinations of Bevacizumab With Cancer Immunotherapy.
Chen DS; Hurwitz H
Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
[TBL] [Abstract][Full Text] [Related]
4. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Bourhis M; Palle J; Galy-Fauroux I; Terme M
Front Immunol; 2021; 12():616837. PubMed ID: 33854498
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
6. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
Tie J; Desai J
Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
[TBL] [Abstract][Full Text] [Related]
8. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
11. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Collins TS; Hurwitz HI
Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
13. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
14. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
15. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
16. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Lee WS; Yang H; Chon HJ; Kim C
Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Mueller T; Freystein J; Lucas H; Schmoll HJ
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
[TBL] [Abstract][Full Text] [Related]
19. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products.
Wahl O; Oswald M; Tretzel L; Herres E; Arend J; Efferth T
Curr Med Chem; 2011; 18(21):3136-55. PubMed ID: 21671856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]